Hereditäres Mamma- und Ovarialkarzinom - ein Update Teil I - molekulare Grundlagen, Tumorrisikoberatung und Risikoberechnung

P. A. Fasching; M. P. Lux; M. Bani; M. W. Beckmann

doi:10.1055/s-2004-821050

Geburtshilfe und Frauenheilkunde, Table of Contents

Geburtshilfe Frauenheilkd 2004; 64(9): 900-911
DOI: 10.1055/s-2004-821050

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Hereditäres Mamma- und Ovarialkarzinom - ein Update Teil I - molekulare Grundlagen, Tumorrisikoberatung und Risikoberechnung

Hereditary Breast and Ovarian Cancer - an Update Part I Molecular Basics, Genetic Counselling and Risk CalculationP. A. Fasching¹ , M. P. Lux¹ , M. Bani¹ , M. W. Beckmann¹

¹Universitätsfrauenklinikum Erlangen

Abstract

Zusammenfassung

Das Mammakarzinom ist bei weitem die häufigste Karzinomdiagnose der Frau. Das kumulative Risiko für eine Erkrankung beträgt 10 % bis zum 80. Lebensjahr. Die Risikofaktoren für die Mammakarzinomentstehung sind vielfältig. Ein wesentlicher Risikofaktor ist die familiäre Belastung. 5 - 10 % aller und 25 - 40 % der Mammakarzinome vor dem 35. Lebensjahr sind genetisch bedingt. 3 - 8 % aller Mammakarzinome und 15 - 20 % aller familiären Mammakarzinome sind durch BRCA1/2-Mutationen bedingt. Das Ovarialkarzinom basiert in 10 % der Fälle auf einer genetischen Prädisposition. Ca. 80 % aller Familien mit familiärer Ovarialkarzinombelastung sind mit BRCA1-Mutationen und ca. 15 % mit BRCA2-Mutationen assoziiert. Eine Anzahl weiterer Gene mit Assoziation zum familiären Mamma- und Ovarialkarzinomsyndrom wurden bereits in den letzten Jahren identifiziert (Hoch- und Niedrig-Penetranz-Gene, risk modifier). Dieses zeigt, dass es sich um ein komplexes Phänomen handelt, das vermutlich multifaktoriell bedingt ist.

BRCA1/2-assoziierte Karzinome zeigen spezielle pathologische Charakteristika, insbesondere eine hohe Mitoserate, erhöhte Pleomorphie, vermehrte Proliferationsraten, niedrige Differenzierung und ein vermehrtes Auftreten von Grad-III-Tumoren. Zudem ist in BRCA1-assoziierten Karzinomen die Östrogen- und Progesteronrezeptorexpression gegenüber sporadischen Karzinomen reduziert. Bei den hereditären und sporadischen Ovarialkarzinomen sind die meisten klinisch-pathologischen Charakteristika ähnlich.

Im Rahmen spezieller interdisziplinärer Tumorrisikosprechstunden können Frauen mit familiärer Belastung beraten und betreut werden. Eine genetische Analyse kann angeboten werden. Risikoberechnungsprogramme können das Risiko näher definieren. Es existiert eine Anzahl an verfügbaren Berechnungsmodellen, welche klinische Entscheidungen bezüglich genetischer Testung, Prävention, prophylaktischer Chirurgie und Früherkennung unterstützen können.

Abstract

Breast cancer is the most frequent carcinoma in women. The cumulative risk for disease is 10 % up to the age of 80. The risk factors for breast cancer are manifold. An important factor is the familial history of breast and ovarian cancer. 5 - 10 % of all breast cancer cases and 25 - 40 % of breast cancer cases prior to the age of 35 have a hereditary origin. BRCA1/2 mutations are responsible for 3 - 8 % of all and 15 - 20 % of familial breast cancer cases. 10 % of ovarian cancer cases have a genetic predisposition. About 80 % (15 %) of all families with a history of ovarian cancer cases are associated with BRCA1 (BRCA2) mutations. A number of other genes, which are associated with familial breast and ovarian cancer syndrome, have been identified in the last years (high and low penetrance genes, risk modifier). This demonstrates that the syndrome is a complex phenomenon.

BRCA1/2-associated breast carcinoma present special pathological characteristics. They have a higher mitotic rate, higher pleomorphy, higher proliferation rates, a lower differentiation and are more often associated with grade III tumours. Moreover, BRCA1-associated carcinoma show no expression of the estrogen and progesteron receptor. Hereditary and sporadic ovarian cancer presents similar pathological characteristics. In the context of interdisciplinary genetic cancer clinics, women at risk can be informed and advised. Women who fullfil the inclusion criteria for genetic testing can have access to analysis.

Risk calculation programs can define the risk. There are several calculation models which assist in making decisions for genetic testing, chemoprevention, prophylactical surgery and intensified early cancer detection programs.

Schlüsselwörter

Hereditäres Mammakarzinom - hereditäres Ovarialkarzinom - BRCA - familiäres Risiko - prädiktive genetische Testung - Risikoberechnung

Key words

Hereditary breast cancer - hereditary ovarian cancer - BRCA - familial risk - predictive genetic testing - risk estimation

Full Text

References

Literatur

1 Beckmann M W, Fasching P A, Lux M P, Klemt D, Schroer B, Bodden-Heidrich R, Goecke T O, Niederacher D, Nestle-Krämling C. Das familiäre Mammakarzinom-Syndrom: prädiktive genetische Testung, Beratung und Betreuung. Medizinische Welt. 2001; 52 385-390
2 Ponder B AJ. Cancer genetics. Nature. 2001; 411 336-341
3 Easton D F. Familial risks of breast cancer. Breast Cancer Res. 2002; 4 179-181
4 Boyd J. Molecular genetics of hereditary ovarian cancer. Rubin SC, Sutton GP Ovarian cancer. 2nd ed. Philadelphia; Lippincott Williams & Wilkins 2001: 3-17
5 Easton. on behalf of the BCLC .Familial Breast Cancer Risks and the BCLC Database. The Breast Cancer Linkage Consortium (BCLC) and the International Collaborative Group on Familial Breast and Ovarian Cancer (ICG-FBOC). 14th General Meeting, Madrid, June 2nd - 4th 2003
6 Lux M P, Fasching P, Bani M, Löhberg C, Pöhls U G, Ackermann S, Beckmann M W. Prophylaktische Therapieoptionen bei Hereditary non-polyposis colorectal cancer (HNPCC)-assozierten gynäkologischen Malignomen. Prophylaktische Chirurgie bei hereditären Tumoren - ein interdisziplinäres Konzept. Sympomed-Kongressband. 2004 in press
7 Pfleiderer A. Möglichkeiten des Tumor-Screenings in der Gynäkologie. Frauenarzt. 1995; 8 893-900
8 Eccles D M, Simmonds P, Goddard J. et al . Management of hereditary breast cancer. European Familial Breast Cancer Collaborative Group. Dis Markers. 1999; 15 187-189
9 Kiechle M, Schmutzler R K, Beckmann M W. Prävention: Familiäres Mamma- und Ovarialkarzinom. Deutsches Ärzteblatt. 2002; 99 A-1372
10 Beckmann M W, Lux M P. Prädiktive Diagnostik und präventive Maßnahmen - hereditäres Mammakarzinom. Onkologe. 2004; in press
11 Beckmann M W, Fasching P A, Weiss J M, Magener A, Ortmann O. Update primäres Mammakarzinom 2003 - GebFra-Refresher. Geburtsh Frauenheilk. 2003; 63 R65-85
12 Ries L AG, Eisner M P, Kosary C L. et al .SEER cancer statistics review, 1973 - 1999. 2002 (Accessed April 1, 2003, at http://seer.cancer.gov/csr/1973_1999/). Bethesda, Md.; National Cancer Institute 2003
13 Ries L AG, Kosary C L, Hankey B F, Miller B A, Harras A, Edwards B K. Surveillance, Epidemiology, and End results (SEER) Program (web site). http://www-seer.ims.nci.nih.gov . Bethesda, MD; National Institutes of Health 1998
14 Brekelmans C T. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol. 2003; 15 63-68
15 Page D L, Schuyler P A, Dupont W D, Jensen R A, Plummer W D, Simpson J F. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003; 361 (9352) 125-129
16 Collaborative Group on Hormonal Factors in Breast Cancer . Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without disease. Lancet. 2001; 358 1389-1399
17 Wooster R, Weber B L. Breast and ovarian cancer. N Engl J Med. 2003; 348 2339-2347
18 Haffty B G, Harrold B G, Khan A J. et al . Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002; 359 1471-1477
19 Easton D F, Bishop D T, Ford D. et al . Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343 692
20 Easton D F, Ford D, Bishop D T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56 256-271
21 Malone K E, Daling J R, Neal C. et al . Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000; 88 1393-1402
22 Loman N, Johannsson O, Kristoffersson U. et al . Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst. 2001; 93 1215-1223
23 Krämer S, Ackermann S, Fasching P A, Kreis H, Pöhls U, Beckmann M W. Steroidhormone und Ovarialkarzinom: Risiken und Nutzen. Geburtsh Frauenheilk. 2003; 63 615-623
24 Risch H A, McLaughlin J R, Cole D EC. et al . Prevalence and penetrance of germline BRCA1 and BRCA2 mutation in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68 700-710
25 Hemminki K, Granström C. Familial invasive and borderline ovarian tumors by proband status, age and histology. Int J Cancer. 2003; 105 701-705
26 Adami H O, Hsieh C C, Lambe M. Parity, age of first childbirth, and risk of ovarian cancer. Lancet. 1994; 344 1250-1254
27 King M C, Marks J H, Mandell J B. for The New York Breast Cancer Study Group . Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science. 2003; 302 643-646
28 Breast Cancer Linkage Consortium . Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999; 91 1310-1316
29 Antoniou A, Pharoah P D, Narod S, Risch H A, Eyfjord J E. et al . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case C series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72 1117-1130
30 Levy-Lahad E, Plon S E. A risky business - assessing breast cancer risk. Science. 2003; 302 574-575
31 Beckmann M W, Strick R, Strissel P L, Fasching P A, Oppelt P, Pöhls U G, Malur S U, Ackermann S. Aspects of molecular diagnostics and therapy in obstetrics and gynecology. Expert Rev Mol Diagn. 2003; 3 279-287
32 Allinen M, Huusko P, Mäntyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHEK2 gene in families with hereditary breast cancer. Br J Cancer. 2000; 85 209-212
33 Watson P, Bützow R, Lynch H AT, Mecklin J P, Järvinen H J, Vasen H FA, Madlensky L, Fidalgo P, Bernstein I. the International Collaborative Group on HNPCC . The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001; 82 223-228
34 Olsen J H, Hanemann J M, Borresen-Dale A L, Brondum-Neilsen K, Hammarstrom L, Kleinerman R, Kaarianen H, Lonnqvist T, Sankila R, Seersholm N. et al . Cancer patients with Ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst. 2001; 93 121-127
35 Dunning A M, Healey C S, Pharoah P D, Teare M D, Ponder B A, Easton D F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999; 8 843-854
36 De Jong M M, Nolte I M, te Meermann G J, van der Graaf W TA, Oosterwijk J C, Kleibeuker L H, Schaapveld M, de Vries E GE. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet. 2002; 39 225-242
37 Nathanson K L, Weber L. “Other” breast cancer susceptibility genes: searching for more holy grail. Hum Mol Gen. 2003; 10 715-720
38 Szelei J, Jimenez J, Soto A M, Luizzi M F, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997; 138 1406-1412
39 Rebbeck T R, Kantoff P W, Krithivas K, Neuhausen S, Blackwood M A, Godwin A K, Daly M B, Narod S A, Garber J E, Lynch H T. et al . Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999; 64 1371-1377
40 Runnebaum I B, Wang-Gohrke S, Vesprini D, Moslehi R, Brunet S, Kieback D G, Narod S A. Progesterone receptor variant and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. AACR Proceedings. 2000; 804
41 Evans H S, Lewis C M, Robinson D, Bell C MJ, Møller H, Hodgson S V. Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer. 2001; 94 758-759
42 Thompson D, Easton D F. Breast Cancer Linkage Consortium . Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94 1358-1365
43 Hemminki K, Vaittinen P, Easton D. Familial cancer risks to offspring from mothers with two primary breast cancers: leads to cancer syndromes. Int J Cancer. 2000; 88 87-91
44 Ford D, Easton D F, Bishop D T. et al . Risks of cancer in BRCA1-mutation carriers. Lancet. 1994; 343 692-695
45 Eisinger F, Jacquemier J, Charpin C. et al . Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 1998; 58 1588-1592
46 Lakhani S, Jacquemier J, Sloane J P. et al . Multifractional analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998; 90 1138-1145
47 Lakhani S R. The Breast Cancer Linkage Consortium (BCLC) and the International Collaborative Group on Familial Breast and Ovarian Cancer (ICG-FBOC). 14th General Meeting, Madrid, June 2nd - 4th 2003
48 Lakhani S R, van de Vijver M J, Jacqemier J, Anderson T J, Osin P P, McGuffog L, Easton D F. The pathology of familial breast cancer: Predictive value of immunhistochemical markers estrogen receptor, progesterone receptor, her-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002; 20 2310-2318
49 Adem C, Reynolds C, Soderberg C L, Slezak J M, McDonnell S K, Sebo T J, Schaid D J, Myers J L, Sellers T A, Hartmann L C, Jenkins R B. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer. 2003; 97 1-11
50 Ford D, Easton D F, Stratton M, Narod S A, Goldgar D E, Devilee P. et al . Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Gen. 1998; 62 676-689
51 Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, Palli D. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003; 63 342-347
52 Wolber R A, Dupuis B A, Wick M R. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 1991; 96 243-247
53 Pharoah P D, Easton D F, Stochton D L, Gayther S, Ponder B A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res. 1999; 59 868-871
54 Boyd J, Sonoda Y, Federici M G, Bogomolniy F, Rhei E, Maresco D L. et al . Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000; 283 2260-2265
55 Levine D A, Federici M G, Reuter V E, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol. 2002; 85 431-434
56 Rhei E, Bogomolniy F, Federici M G, Maresco D L, Offit K, Robson M E, Saigo P E, Boyd J. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res. 1998; 58 3193-3196
57 Cass I, Baldwin R L, Varkey T, Moslehi R, Narod S A, Karlan B Y. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003; 97 2187-2195
58 Kuschel B, Lux M P, Goecke T O, Beckmann M W. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer. Eur J Cancer Prev. 2000; 9 139-150
59 Brody L C, Bieecker B B. Breast cancer susceptibility genes: BRCA1 and BRCA2. Medicine. 1998; 77 208-226
60 Lastao L, Joiner T E, Pettit J W, Chorot P, Sandin B. Health belief and illness attitudes as predictors of breast cancer screening attendance. Eur J Public Health. 2001; 11 274-279
61 Niederacher D, Kiechle M, Arnold N. Molekular- und zytogenetische Techniken in der Onkologie. Gynäkologe. 1998; 31 1012-1018
62 German Consortium for hereditary Breast and Ovarian Cancer . Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002; 97 472-480
63 Meijers-Heijbouer H, Brekelmans C TM, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland A WM, van Geel B, Klijn J GM. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003; 21 1675-1681
64 Lee S C, Bernhardt B A, Helzsouer K J. Utilization of BRCA1/2 genetic testing in the clinical setting. Cancer. 2002; 94 1876-1885
65 Gail M H, Brinton L A, Byar D P. et al . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81 1879-1886
66 Claus E B, Risch N, Thompson W D. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991; 48 232-242
67 Claus E B, Thompson W D, Risch N. The calculation of breast cancer risk for women with a first degree familiy of ovarian cancer. Breast Cancer Res Treat. 1993; 28 115-120
68 Claus E B, Risch N, Thompson W D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994; 73 643-651
69 Berry D A, Parmigiani G, Sanchez J. et al . Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997; 89 227-238
70 Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62 145-158
71 Struewing J P, Abeliovich D, Peretz T. et al . The carrier frequency of the BRCA1 185 delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995; 11 198-200
72 Claus E B, Schildkraut J M, Thompson W D. et al . The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77 2318-2324
73 Anderson H. Familial Breast and Ovarian Cancer: A Swedish population-based register study. Am J Epidemiol. 2000; 152 1154-1163
74 Tyrer J P, Duffy S W, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004; 23 1111-1130
75 Amir E, Evans D G, Shenton A. et al . Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003; 40 807-814
76 Meijers-Heijboer H, van den Ouweland A, Klijn J. et al . Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100 delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002; 31 55-59
77 Fasching P, Aichinger U, Schulz-Wendtland R, Beckmann M W. GebFra-Refresher - Mammadiagnostik Teil II. Geburtsh Frauenheilk. 2001; 61 R17-32

Dr. med. P. A. Fasching

Frauenklinik - Universitätsklinikum Erlangen

Universitätsstraße 21 - 23

91054 Erlangen

Email: peter.fasching@gyn.imed.uni-erlangen.de